NI201100007A - Compuestos químicos 251. - Google Patents

Compuestos químicos 251.

Info

Publication number
NI201100007A
NI201100007A NI201100007A NI201100007A NI201100007A NI 201100007 A NI201100007 A NI 201100007A NI 201100007 A NI201100007 A NI 201100007A NI 201100007 A NI201100007 A NI 201100007A NI 201100007 A NI201100007 A NI 201100007A
Authority
NI
Nicaragua
Prior art keywords
pim
chemical compounds
relates
kinase
modulators
Prior art date
Application number
NI201100007A
Other languages
English (en)
Inventor
Dakin Leslie
Su Qibin
Zheng Xiaolan
Edward Dowling James
Lamb Michelle
Read Jon
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41050276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201100007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201100007A publication Critical patent/NI201100007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La invención se refiere a compuestos químicos de fórmula I, y sales de los mismos. En algunas realizaciones, la invención se refiere a inhibidores o moduladores de la actividad o función enzimática de la proteína quinasa PIM-1 y/o PIM-2 y/o PIM-3. En otras realizaciones adicionales, la invención se refiere a composiciones farmacéuticas que comprenden compuestos descritos en la presente y su uso en la prevención y tratamiento de afecciones y enfermedades relacionadas con la quinasa PIM, preferiblemente cáncer.
NI201100007A 2008-07-02 2011-01-05 Compuestos químicos 251. NI201100007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7763908P 2008-07-02 2008-07-02
US18327809P 2009-06-02 2009-06-02

Publications (1)

Publication Number Publication Date
NI201100007A true NI201100007A (es) 2011-12-15

Family

ID=41050276

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100007A NI201100007A (es) 2008-07-02 2011-01-05 Compuestos químicos 251.

Country Status (27)

Country Link
US (2) US8901307B2 (es)
EP (1) EP2310010A2 (es)
JP (2) JP5261575B2 (es)
KR (1) KR20110031367A (es)
CN (2) CN103804371A (es)
AR (1) AR072791A1 (es)
AU (1) AU2009265362B2 (es)
BR (1) BRPI0914599A2 (es)
CA (1) CA2729557A1 (es)
CL (1) CL2010001636A1 (es)
CO (1) CO6341555A2 (es)
CR (1) CR20110016A (es)
DO (1) DOP2010000408A (es)
EA (1) EA018989B1 (es)
EC (1) ECSP10010735A (es)
HN (1) HN2010002786A (es)
IL (1) IL210127A0 (es)
MX (1) MX2010014233A (es)
MY (1) MY155961A (es)
NI (1) NI201100007A (es)
NZ (1) NZ590859A (es)
PE (1) PE20120304A1 (es)
SV (1) SV2011003786A (es)
TW (1) TWI461423B (es)
UY (1) UY31952A (es)
WO (1) WO2010001169A2 (es)
ZA (1) ZA201100844B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201319063A (zh) * 2011-10-04 2013-05-16 Yakult Honsha Kk 以四氫噻唑衍生物或其鹽為有效成分之醫藥品
US9422246B2 (en) 2012-03-30 2016-08-23 Rohto Pharmaceutical Co., Ltd. Benzylidene azolidine derivative or salt thereof
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
JP6299591B2 (ja) * 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
JP6378918B2 (ja) * 2013-04-03 2018-08-22 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とするＰｉｍ阻害剤
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
JP5799148B2 (ja) * 2013-09-27 2015-10-21 ロート製薬株式会社 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
WO2015046390A1 (ja) * 2013-09-27 2015-04-02 ロート製薬株式会社 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
WO2015122504A1 (ja) * 2014-02-13 2015-08-20 国立大学法人 東京大学 キナーゼ阻害剤
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP5857104B2 (ja) * 2014-06-17 2016-02-10 ロート製薬株式会社 ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016100391A1 (en) 2014-12-15 2016-06-23 Prosetta Antiviral, Inc. 2-phenethenyltetrahydro isoquinolines useful as anti-hiv compounds
CN105985298B (zh) * 2015-02-10 2018-02-23 湖南大学 2‑[(5‑卤噻唑‑2‑基)亚氨基]‑5‑亚苄基噻唑啉酮及其制备方法与应用
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
CN106032365B (zh) * 2015-03-11 2018-03-23 湖南大学 2‑(噻唑‑2‑基)亚氨基‑5‑亚苄基噻唑啉酮及其制备方法与应用
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
CN109475565B (zh) 2016-04-05 2021-11-02 免疫传感器公司 cGAS拮抗剂化合物
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
MA45244A (fr) 2016-06-13 2019-04-17 Cancer Research Tech Ltd Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
PH12019502776A1 (en) * 2017-06-30 2020-10-26 Univ California Compositions and methods for modulating hair growth
US11319320B2 (en) 2017-11-06 2022-05-03 Snap Bio, Inc. PIM kinase inhibitor compositions, methods, and uses thereof
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション （１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
WO2019209083A1 (ko) * 2018-04-26 2019-10-31 재단법인 의약바이오컨버젼스연구단 mTOR 저해제로서의 신규 화합물 및 이의 용도
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US12559490B2 (en) 2020-06-30 2026-02-24 The Regents Of The University Of California Compositions and methods for modulating hair growth
WO2022086920A1 (en) * 2020-10-20 2022-04-28 Blacksmith Medicines, Inc. Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
WO2023039170A1 (en) * 2021-09-09 2023-03-16 Musc Foundation For Research Development Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy
CN116354901B (zh) * 2023-04-12 2024-04-26 郑州大学 一种噻唑烷二酮类化合物及其制备方法和应用
WO2025017207A1 (en) 2023-07-20 2025-01-23 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibitors of smndc1 and their therapeutic use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
CZ289317B6 (cs) * 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
JP3668291B2 (ja) 1995-06-16 2005-07-06 久光製薬株式会社 新規なピペリジン誘導体
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA56185C2 (uk) 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU6340600A (en) * 1999-07-01 2001-01-22 Geron Corporation Telomerase inhibitors and methods of their use
TW593293B (en) * 1999-08-23 2004-06-21 Kyorin Seiyaku Kk Substituted benzylthiazolidine-2,4-dione derivatives
WO2001014349A1 (en) 1999-08-23 2001-03-01 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
AU1595001A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
EA011807B1 (ru) 2002-07-10 2009-06-30 Лаборатуар Сероно Са Азолидинонвинильные производные конденсированного бензола
ZA200509355B (en) * 2003-04-18 2007-03-28 Incyte San Diego Inc Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
JP2007535551A (ja) 2004-04-28 2007-12-06 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｒｏｃｋおよび他のプロテインキナーゼの阻害剤として有用な組成物
WO2006069186A2 (en) * 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
WO2009064486A2 (en) * 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim

Also Published As

Publication number Publication date
AU2009265362A1 (en) 2010-01-07
ZA201100844B (en) 2011-10-26
EA018989B1 (ru) 2013-12-30
CR20110016A (es) 2011-03-11
IL210127A0 (en) 2011-02-28
MX2010014233A (es) 2011-03-25
WO2010001169A3 (en) 2010-08-05
AR072791A1 (es) 2010-09-22
US8901307B2 (en) 2014-12-02
JP5261575B2 (ja) 2013-08-14
ECSP10010735A (es) 2011-01-31
TWI461423B (zh) 2014-11-21
US20110218182A1 (en) 2011-09-08
CN103804371A (zh) 2014-05-21
CO6341555A2 (es) 2011-11-21
WO2010001169A2 (en) 2010-01-07
BRPI0914599A2 (pt) 2017-06-06
TW201004949A (en) 2010-02-01
US20150051185A1 (en) 2015-02-19
CN102137666B (zh) 2014-03-12
AU2009265362B2 (en) 2012-07-19
UY31952A (es) 2010-01-29
CN102137666A (zh) 2011-07-27
HN2010002786A (es) 2013-01-28
EP2310010A2 (en) 2011-04-20
DOP2010000408A (es) 2011-02-28
KR20110031367A (ko) 2011-03-25
CL2010001636A1 (es) 2011-07-15
JP2011526616A (ja) 2011-10-13
PE20120304A1 (es) 2012-04-22
SV2011003786A (es) 2011-05-13
MY155961A (en) 2015-12-31
EA201100119A1 (ru) 2011-08-30
NZ590859A (en) 2012-08-31
CA2729557A1 (en) 2010-01-07
JP2013139459A (ja) 2013-07-18

Similar Documents

Publication Publication Date Title
DOP2010000408A (es) Compuestos quimicos 251
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
BRPI0712816B8 (pt) compostos de pirrolpirimidina e seus usos
ECSP088152A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
CL2009000967A1 (es) Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente.
BRPI0719195B8 (pt) inibidores de quinase, seus usos, e composição farmacêutica
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
EA200870019A1 (ru) Лактамовые соединения и способы их применения
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
MX384206B (es) Formulaciones de inhibidores de dpp iv
SV2010003706A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
ECSP099776A (es) Moduladores de la gamma secretasa
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
ECSP109968A (es) Depsipéptidos cíclicos
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
BRPI0520806A2 (pt) derivados pirrólicos, processos para a preparação de compostos, seu uso e composição farmacêutica que os contém
CU23957B1 (es) Derivados de tiazolidin-2,4-diona